Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Craig Andrew Miller

Derek Cogan

Donghong Amy Gao

Pingrong Liu

Sabine Ruppel

Zhonghua Zhang

Matthew Russell Netherton

Anil Kumar Padyana

Maolin Yu

Alexander Heim-Riether

Bryan Patrick McKibben

Philip Dean Ramsden

Daniel R Goldberg

Neil Moss

Ming-Hong Hao

Rene Marc Lemieux

Roger John Snow

Alan David Swinamer

Zhaoming Xiong

Lana Louise Smith Keenan

Steven Richard Brunette

Victor Marc Kamhi

Jennifer A Kowalski

Joshua Courtney Horan

Yang Yu

Michael David Lawlor

Weimin Liu

Hossein Razavi

Zhidong Chen

Jiang-Ping Wu

Matt Aaron Tschantz

Asitha Abeywardane

Wang Mao

Joerg Bentzien

Hui Yu

Antonio J M Barbosa, Jr

Jianwen Cui

Elizabeth Spencer

Antonio Jose Del Moral Barbosa, Jr

Yu Yang

Younggi Choi

Anil K Padayana

Bryan Patrick Mckibben

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

Antonio JM Barbosa

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Substituted benzamides as RIPK2 inhibitors for treatment of inflammatory bowel disease

Substituted benzamides as RIPK2 inhibitors

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R&#x2014;, R&#x2014;, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed is a compound of formula (I). Wherein R, RAr and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10. 

[object Object]

This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R, R, R. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10. 

2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

The application relates to compounds of formula Ia and analogues thereof wherein Rto Rand X are as defined herein. The invention also relates to the use of the compounds of formula Ia as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.

Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors

Disclosed compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Anti-cytokine heterocyclic compounds

Growing community of inventors

Norwalk, CT, United States of America

Craig Andrew Miller